Étiquette : essais cliniques

Cannabis and cannabinoid use in autism spectrum disorder : a systematic review, Estácio Amaro da Silva Junior et al., 2021

Cannabis and cannabinoid use in autism spectrum disorder : a systematic review Estácio Amaro da Silva Junior, Wandersonia Moreira Brito Medeiros, Nelson Torro, João Marçal Medeiros de Sousa, Igor Bronzeado Cahino Moura de Almeida, Filipe Barbosa da Costa, Katiúscia Moreira Pontes, Eliane Lima Guerra Nunes, Marine Diniz da Rosa, Katy Lísias Gondim Dias de Albuquerque Trends in Psychiatry and Psychotherapy, 2021, 1-10. Doi : 10.47626/2237-6089-2020-0149 Abstract Introduction : Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by persistent deficits in social communication and social interaction, associated with the presence of restricted and repetitive patterns of behavior, interests, or activities. Cannabis has been used to alleviate [...]

Lire la suite

Bibliographie : Kétamine, Dr Christian Sueur, GRECC, mai 2021

Bibliographie : Kétamine Dr Christian Sueur, GRECC, (mai 2021)   Kétamine en Psychiatrie : 1 - 3 Usages thérapeutiques en médecine psychédélique : 4 Kétamine et psychose : 5 - 6 Kétamine et traitement de la dépression : 7 - 20 Kétamine et prise en charge de l’idéation suicidaire : 21 - 22 Kétamine et traitement de la dépression chez les enfants et adolescents : 23 - 24 Kétamine et prise en charge des troubles psychotraumatiques (PTSD) : 25 - 27 Ketamine et addictions : 28 - 29 Kétamine et sevrage des opiacés : 30 Kétamine et prise en charge de la douleur : 31 - 32 Kétamine et prise en charge de [...]

Lire la suite

Cannabidiol Adverse Effects and Toxicity, Marilyn A. Huestis et al., 2019

Cannabidiol Adverse Effects and Toxicity Marilyn A. Huestis, Renata Solimini, Simona Pichini, Roberta Pacifici, Jeremy Carlier and Francesco Paolo Busardò Current Neuropharmacology, 2019, 17, 974-989 Doi : 10.2174/1570159XI7666190603171901 Abstract : Background : Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD occurred in the 1970s and intensified recently with many discoveries about the endocannabinoid system. Multiple preclinical and clinical studies led to FDA-approval of Epidiolex®, a purified CBD medicine formulated for oral administration for the treatment of infantile refractory epileptic syndromes, by the US Food and Drug Administration in 2018. The World [...]

Lire la suite

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol, Douglas L Boggs et al., 2018

Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L Boggs, Jacques D Nguyen, Daralyn Morgenson, Michael A Taffe and Mohini Ranganathan Neuropsychopharmacology Reviews, 2018, 43, 142–154. doi : 10.1038/npp.2017.209; The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for medical purposes. There are 4550 chemical compounds and 4100 phytocannabinoids [...]

Lire la suite

Reviewing the Potential of Psychedelics for the Treatment of PTSD, Erwin Krediet et al., 2020

Reviewing the Potential of Psychedelics for the Treatment of PTSD Erwin Krediet, Tijmen Bostoen, Joost Breeksema, Annette van Schagen, Torsten Passie, Eric Vermetten International Journal of Neuropsychopharmacology, 2020, 23, (6), 385–400 doi : 10.1093/ijnp/pyaa018 https://pubmed.ncbi.nlm.nih.gov/32170326/   Abstract There are few medications with demonstrated efficacy for the treatment of posttraumatic stress disorder (PTSD). Treatment guidelines have unequivocally designated psychotherapy as a first line treatment for PTSD. Yet, even after psychotherapy, PTSD often remains a chronic illness, with high rates of psychiatric and medical comorbidity. Meanwhile, the search for and development of drugs with new mechanisms of action has stalled. Therefore, there is an urgent need to explore not [...]

Lire la suite

The experimental effects of psilocybin on symptoms of anxiety and depression : A meta-analysis, Simon B. Goldberg et al, 2020

The experimental effects of psilocybin on symptoms of anxiety and depression : A meta-analysis Simon B. Goldberg, Brian T. Pace, Christopher R. Nicholas, Charles L. Raison, Paul R. Hutson Psychiatry Research, 2020, 284,  112749 Doi : 10.1016/j.psychres.2020.112749   A B S T R A C T The current meta-analysis examined the effects of psilocybin in combination with behavioral interventions on anxiety and depression in samples with elevated symptoms. Across four studies (one uncontrolled; three randomized, placebo-controlled; N = 117), within-group pre-post and pre-follow-up effects on anxiety and depression were large (Hedges’ gs=1.16 to 1.47) and statistically significant. Across three placebo-controlled studies, pre-post placebo-controlled effects were also [...]

Lire la suite

Post-acute psychological effects of classical serotonergic psychedelics : a systematic review and meta-analysis, Simon B. Goldberg et al, 2020,

Post-acute psychological effects of classical serotonergic psychedelics: a systematic review and meta-analysis Simon B. Goldberg, Benjamin Shechet, Christopher R. Nicholas, Chi Wing Ng, Geetanjali Deole, Zhuofan Chen and Charles L. Raison Psychological Medicine, 2020, 1–12. doi : 10.1017/S003329172000389X   Abstract Background. Scientific interest in the therapeutic effects of classical psychedelics has increased in the past two decades. The psychological effects of these substances outside the period of acute intoxication have not been fully characterized. This study aimed to: (1) quantify the effects of psilocybin, ayahuasca, and lysergic acid diethylamide (LSD) on psychological outcomes in the post-acute period; (2) test moderators of these effects; and (3) evaluate [...]

Lire la suite

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD) : a systematic review of clinical trials published in the last 25 years, Raphael G. dos Santos et al., 2016

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD) : a systematic review of clinical trials published in the last 25 years Rafael G. dos Santos, Flávia L. Osório, José Alexandre S. Crippa, Jordi Riba, Antônio W. Zuardi and Jaime E. C. Hallak Therapeutic Advances in Psychopharmacology, 2016, Vol. 6, (3) 193–213 Doi : 10.1177/2045125316638008   Abstract : To date, pharmacological treatments for mood and anxiety disorders and for drug dependence show limited efficacy, leaving a large number of patients suffering severe and persistent symptoms. Preliminary studies in animals and humans suggest that ayahuasca, psilocybin and lysergic acid diethylamide (LSD) may have [...]

Lire la suite

Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder. A Systematic Review, Maya E. O’Neil et al., 2020

Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder. A Systematic Review Maya E. O’Neil, PhD; Shannon M. Nugent, PhD; Benjamin J. Morasco, PhD; Michele Freeman, MPH; Allison Low, BA; Karli Kondo, PhD; Bernadette Zakher, MBBS; Camille Elven, MD; Makalapua Motu’apuaka, BA; Robin Paynter, MLIS; and Devan Kansagara, MD, MCR Annals of Internal Medicine, 2020 doi : 10.7326/M17-0477   Background : Cannabis is available from medical dispensaries for treating posttraumatic stress disorder (PTSD) in many states of the union, yet its efficacy in treating PTSD symptoms remains uncertain. Purpose : To identify ongoing studies and review existing evidence regarding the benefits and harms of plant-based [...]

Lire la suite

Infection VIH et cannabinoides. Etat des lieux et pistes en recherche clinique, Roland Tubiana et Fabienne Caby, RESPADD – GRECC, 2019

Infection VIH et cannabinoides. Etat des lieux et pistes en recherche clinique Roland Tubiana et Fabienne Caby, 24e Rencontres du RESPADD - GRECC, "Usages Cliniques des Cannabinoïdes" 21 juin 2019   (...) Inflammation/ Activation immune et CB Chez les PVVIH traités efficacement, la consommation de CB a été associée: – À des niveaux moins élevés de marqueurs d’inflammation (L B TNF-α+ )/ activation immune (L TCD4+ et CD8+ HLA-DR+CD38+) – A une décroissance plus rapide du niveau d’ADN proviralVIH Mécanismes sous jacents CB (Cannabis Sativa) : > 60 cannabinoides, > 200 non cannabinoides • Cannabinoides: Composant capables d’activer la proteine G couplée aux récepteurs CB1 ou CB2 • Les 2 plus étudiés: Δ9-THC [...]

Lire la suite